Home › Research › Mild cognitive impairment
Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview
Brosseron F, Krauthausen M, Kummer M, Heneka MT.. Molecular neurobiology, 2014-02-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This article gives a comprehensive overview of cytokine and other inflammation associated protein levels in plasma, serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI). We reviewed 118 research articles published between 1989 and 2013 to compare the reported levels of 66 cytokines and other proteins related to regulation and signaling in inflammation in the blood or CSF obtained from MCI and AD patients. Several cytokines are evidently regulated in (neuro-) inflammatory processes associated with neurodegenerative disorders. Others do not display changes in the blood or CSF during disease progression. However, many reports on cytokine levels in MCI or AD are controversial or inconclusive, particularly those which provide data on frequently investigated cytokines like tumor necrosis factor alpha (TNF-α) or interleukin-6 (IL-6). The levels of several cytokines are possible indicators of neuroinflammation in AD. Some of them might increase steadily during disease progression or temporarily at the time of MCI to AD conversion. Furthermore, elevated body fluid cytokine levels may correlate with an increased risk of conversion from MCI to AD. Yet, research results are conflicting. To overcome interindividual variances and to obtain a more definite description of cytokine regulation and function in neurodegeneration, a high degree of methodical standardization and patients collective characterization, together with longitudinal sampling over years is essential.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This review of 118 articles found that several cytokines are regulated in inflammatory processes associated with neurodegenerative disorders, and that elevated body fluid cytokine levels may correlate with increased risk of conversion from MCI to Alzheimer's. However, the authors note many reports are controversial or inconclusive, so this is not a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014). Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Molecular neurobiology. https://doi.org/10.1007/s12035-014-8657-1
Vancouver
Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Molecular neurobiology. 2014. doi:10.1007/s12035-014-8657-1. PMID: 24567119.
BibTeX
@article{brosseron2014-24567119,
author = {Brosseron, F. and Krauthausen, M. and Kummer, M. and Heneka, M. T.},
title = {{Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview}},
journal = {Molecular neurobiology},
year = {2014},
doi = {10.1007/s12035-014-8657-1},
pmid = {24567119},
url = {https://doi.org/10.1007/s12035-014-8657-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Several cytokines are evidently regulated in (neuro-) inflammatory processes associated with neurodegenerative disorders.
- Furthermore, elevated body fluid cytokine levels may correlate with an increased risk of conversion from MCI to AD.
Why it matters
This review of 118 articles found that several cytokines are regulated in inflammatory processes associated with neurodegenerative disorders, and that elevated body fluid cytokine levels may correlate with increased risk of conversion from MCI to Alzheimer's. However, the authors note many reports are controversial or inconclusive, so this is not a treatment or cure.
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 59/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurobiology) |
| Journal's citation record | 2 / 4 | Molecular Neurobiology: journal h-index 176 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 449 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 32.1 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 4 / 6 | Cited 11.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 19 other studies in this library |
| Still being cited | 3 / 4 | Cited 84 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Michael Thomas Heneka: h-index 113 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University Hospital Bonn: institution h-index 533 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24567119) |
| Free to read | 2 / 2 | Free to read |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s12035-014-8657-1
- PubMed: 24567119
- Original source →
- Free full text: Molecular Neurobiology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
19 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Mild cognitive impairment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.